5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
One under-$10 biopharmaceutical player that's quickly moving within range of triggering a big breakout trade is Sunesis Pharmaceuticals (SNSS) , which focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. This stock has been hammered by the sellers so far in 2014, with shares down huge by 50%.
If you take a glance at the chart for Sunesis Pharmaceuticals, you'll notice that this stock has been uptrending strong over the last two months, with shares moving higher from its low of $1 a share to its recent high of $2.59 a share. During that uptrend, shares of SNSS have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of SNSS within range of triggering a major breakout trade.
Traders should now look for long-biased trades in SNSS if it manages to break out above some key near-term overhead resistance levels at $2.59 a share to its 50-day moving average of $2.88 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.58 million shares. If that breakout triggers soon, then SNSS will set up to re-fill some of its previous gap-down-day zone from October that started around $6.50 a share.
Traders can look to buy SNSS off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2 a share. One can also buy SNSS off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
I'm not concerned. The majority of censoring accrued significantly past the median. Had it accrued before as with most of the censored ASCT it would be a concern. I would be curious what percentage of these censors were for ASCT.
What are your thoughts regarding the high sensor rate for 60+ in the VOS/CYT arm relative to the VOS/PLA control arm? Ie 19.9% versus 10.7%. I wonder if Mr Swisher will address that at the conference.
60 day mortality also drops from 20% to 13% in an older population in SEAMLESS
No greater toxicity???
"Thirty-day and 60-day all-cause mortality was similar in the 2 arms (30-day: 7.9% vs 6.6%; 60-day: 19.7% vs 19.4% with vos/cyt vs pla/cyt, respectively). Most common serious AEs were febrile neutropenia (11.3% with vos/cyt vs 7.4% with pla/cyt), sepsis (8.7% vs 4.3%), pneumonia (7.6% vs 4.9%), bacteremia (8.5% vs 2.9%), and stomatitis (3.4% vs 1.4%). Serious and non-serious cardiac, renal, neurologic, and hepatic AEs were comparable between treatment groups." AE's go DOWN in SEAMLESS (SAP/DAC)
PRE-DEFINED sub group analysis is perfectly legitimate. VOR is far from the definitive drug for AML, but clearly has efficacy in the relapsed/refractory AML group 60 yr. I see no reason why FDA would not grant approval for this group. Elderly relapsed/refractory AML is a particularly challenging group, and even a modest, incremental benefit is worthwhile. VOR/CYT had NO greater toxicity then VOR/PLA. KOL in heme/onc appear to have favorable opinion that VOR should be added to the armamentarium.
Funny, Hold on there cowboy. SEAMLESS hasn't reported interim results yet. Also, it is a "futility analysis" and data will not be un-blinded until top-line. No wonder you weren't impressed. And yes, CR does not predict survival in elderly AML.
Take note, in the SAP/DAC arm of the SEAMLESS study, the alternating cycle regimen is driving 60 day mortalities from 20% in DAC control down to 13% The SAP/DAC combination reduces adverse events while broadening the treatment spectrum. This drop in 60 day mortality obviously leads to a nice early separation in the curve. I tried to engage you in discussion before and you disappeared. Perhaps you might want to respond this time?
Sentiment: Strong Buy
Mghd, understandably SNSS is doing everything in their power to improve their situation. They missed the primary endpoint and they are trying to promote an Ad Hoc subgroup which is still short of FDA requirements. The study shows no improvement in the 60 day mortality rate over control and the concurrent administration yielded overlapping toxicities which drove up adverse events. Also, the significantly higher censor rate seen VOR/CYT arm introduces questions about the reliability of data and tolerability of the regimen.
I am impressed that SNSS is sponsoring a continuing medical education symposium at the ASH meeting. This is usually the domain of big pharma. Vosaroxin will undoubtedly be discussed:
On behalf of the course director, Farhad Ravandi, MD, we thank you for your registration for “New Territory in Acute Leukemia: How Cutting-Edge Science and Novel Therapies Will Change Patient Care.”
This educational symposium is CME-accredited by Penn State College of Medicine and CNE-accredited by the Institute for Advancement of Human Behavior. Please visit www.peerviewpress.com/AML for additional details.
Friday, December 5, 2014
12:30 – 1:00 PM PST: Registration and Lunch
1:00 – 3:00 PM PST: Symposium
Meeting Room: 2001/2003
I think the oral presentation at the special" Late Breaking Abstracts Session" is a big deal. It emphasizes the significance of the data regarding vosaroxiin and it is presented to a large audience..The data will likely be updated to 12/1/14. It will provide validation of the sub group analysis demonstrating the efficacy of the drug.
tyrant or no, your first statement about how few drugs made it in 20 years is the truthful and fair warning to all. believe NOTHING out here. NOTHING